Down-regulation of Egr-1 by siRNA inhibits growth of human prostate carcinoma cell line PC-3

Oncology Reports

Volumn 22, Issue 6, 2009, Pages 1513-1518

  Parra, Eduardo ^a   Ortega, Arnaldo ^a   Saenz, Leonardo ^b  

^a UNIVERSIDAD DE TARAPACÁ   (Chile)

^b UNIVERSITY OF CHILE   (Chile)

Author keywords

Apoptosis; Early growth response gene; Prostate carcinoma; Short RNA interference

Indexed keywords

EARLY GROWTH RESPONSE FACTOR 1; LUCIFERASE; SMALL INTERFERING RNA;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE S PHASE; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROSTATE CANCER; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; WESTERN BLOTTING;

APOPTOSIS; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; EARLY GROWTH RESPONSE PROTEIN 1; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; PROSTATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; RNA, MESSENGER; RNA, SMALL INTERFERING; TETRAZOLIUM SALTS; THIAZOLES;

EID: 70449363841     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000595     Document Type: Article

References (44)

1. Eichelberger L, O Koch M, Eble J, Ulbright T, Juliar B and Cheng L: Maximum tumor diameter is an independent predictor of prostate-specific antigen recurrence in prostate cancer modern pathology. Oncol Rep 18: 886-890, 2005.
2. Virolle T, Krones-Herzig A, Baron V, Gregorio GG, Adamson ED and Mercola D: Egr1 promotes growth and survival of prostate cancer cells: identification of novel Egr1 target genes. J Biol Chem 278: 11802-11810, 2003.
3. Eid MA, Kumar MV, Iczkowski KA, Bostwick DG and Tindall DJ: Expression of early growth response genes in human prostate cancer. Cancer Res 58: 2461-2472, 1998.
4. Scharnhorst V, Menke AL and Attema J: EGR-1 enhances tumor growth and modulates the effect of the Wilms' tumor 1 gene products on tumorigenicity. Oncogene 19: 791-800, 2000.
5. Pignatelli M, Luna-Medina R, Perez-Rendon A, Santos A and Perez-Castillo A: The transcription factor early growth response factor-1 (EGR-1) promotes apoptosis of neuroblastoma cells. Biochem J 373: 739-746, 2003.
6. Houston P, Campbell CJ, Svaren J, Milbrandt J and Braddock M: The transcriptional corepressor NAB2 blocks Egr-1-mediated growth factor activation and agiogenesis. Biochem Biophys Res Commun 283: 480-486, 2001.
7. Collins S, Lutz MA, Zank PA, Anders R, Kersh G and Powell JD: Opposing regulation of T cell function by Egr-1/NAB2 and Egr-2/Egr-3. Eur J Immunol 38: 528-536, 2008.
8. Amorino G, Hamilton V, Valerie K, Dent P, Lammering G and Schmidt-Ullrich R: Epidermal growth factor receptor dependence of radiation-induced transcription factor activation in human breast carcinoma cells. Mol Biol Cell 13: 2233-2244, 2002.
9. Adamson ED and Mercola D: Egr1 transcription factor, multiple roles in prostate tumor cell growth and survival. Tumor Biol 23: 93-102, 2002.
10. Banks MF, Gerasimovskaya EV, Tucker D, Frid MG, Carpenter TC and Stenmark KR: Egr-1 antisense oligonucleotide inhibit hypoxia-induced proliferation of pulmonary artery adventitial fibroblast. J Appl Physiol 98: 732-738, 2004.
11. Huang RP, Fan Y, De Belle I, Niemeyer C, Gottardis MM, Mercola D and Adamson ED: Decreased Egr-1 expression in human, mouse and rat mammary cells and tissues correlates with tumor formation. Int J Cancer 72: 102-109, 1997.
12. Tuschl T and Borkhardt A: Small interfering RNAs a revolutionary tool for the analysis of gene function and gene therapy. Mol Interv 2: 158-167, 2002.
13. Konnikova L, Kotecki M, Kruger MM, Cochran BH and Miao GY: Downregulation of survivin gene expression by RNAi knockdown of STAT3 expression by RNAi induces apoptosis in astrocytoma cells. BMC 3: 23, 2003.
14. Sioud M, Furset G, and Cekaite L: Suppression of immunostimulatory siRNA-driven innate immune activation by 2′-modified RNAs. Biochem Biophys Res Commun 361: 122-126, 2007.
15. Mikio A, Takayuki I, Masaharu K and Toru K: RNA interference in immune cells by use of osmotic delivery of SiRNA. Biochem Biophys Res Commun 360: 326-333, 2006.
16. Sioud M: Does the understanding of immune activation by RNA predict the design of safe siRNA. Front Biosci 13: 4379-4392, 2008.
17. Hannon GJ and Rossi JJ: Unlocking the potential of the human genome with RNA interference. Nature 431: 371-378, 2004.
18. Stevenson M: Therapeutic potential of RNA interference. N Engl J Med 351: 1772-1777, 2004.
19. Devroe E and Silver PA: Retrovirus-delivered siRNA. BMC Biotechnology 2: 15-20, 2002.
20. Persengiev SP, Zhu X and Green MR: Non-specific, concentration-dependent stimulation and repression of mammalian gene expression by small interfering RNAs (siRNA). RNA 10: 12-18, 2004.
21. Sui G, Soohoo C, Affar E, Gay F, Shi Y, Forrester WC and Shi Y: A DNA vector based RNAi technology to suppress gene expression in mammalian cells. Proc Natl Acad Sci USA 99: 5515-5520, 2002.
22. Jackson AL and Linsley PS: The silence: off-target effects of siRNAs? Trends in genetics. Nat Genet 20: 521-524, 2004.
23. Kawasaki H, Taira K and Morris K: siRNA induced transcriptional gene silencing in mammalian cells. Cell Cycle 4: 442-449, 2005.
24. Inostroza J, Saenz L, Calaf G, Cabello G and Parra E: Role of the phosphatase PP4 in the activation of JNK-1 in prostate carcinoma cell lines PC-3 and LNCaP resulting in increased AP-1 and EGR-1 activity. Biol Res 38: 163-178, 2005.
25. Liu C, Rangnekar VM, Adamson E and Mercola D: Suppression of growth and transformation and induction of apoptosis by EGR-1. Cancer Gene Ther 5: 3-28, 1998.
26. Kawasaki H, Altieri DC, Lu CD, Toyoda M, Tenjo T and Tanigawa N: Inhibition of apoptosis by survivin predicts shorter survival rates colorectal cancer. Cancer Res 58: 5071-5074, 1998.
27. Thiel G and Cibelli G: Regulation of life and death by the zinc finger transcription factor Egr-1. J Cell Physiol 193: 287-292, 2002.
28. Huang RP, Fan Y and Peng A: Suppression of human fibro-sarcoma cell growth by transcription factor, Egr-1, involves down-regulation of Bcl-2. Int J Cancer 77: 880-886, 1998.
29. Uchida H, Tanaka T, Sasaki K, Kato K, Dehari H, Ito Y, Kobune M, Miyagishi M, Taira K, Tahara H and Hamada H: Adenovirus-mediated transfer of siRNA against survivin induced apoptosis and attenuated tumor cell growth in vitro and in vivo. Mol Ther 10: 162-171, 2004.
30. Shuangli N, Fuessel S, Kotzsch M, Kraemer K, Kappler M, Schmidt U, Taubert H, Wirth M and Meye A: siRNA-mediated down-regulation of survivin inhibits bladder cancer cell growth. Int J Oncol 25: 1065-1071, 2004.
31. Yong C and Rami M: siRNA pool targeting different sites of human hepatitis B surface antigen efficiently inhibits HBV infection. J Drug Target 16: 140-148, 2008.
32. Kim D and Rossi JJ: Coupling of RNAi-mediated target downregulation with gene replacement. Antisense Nucleic Acid Drug Dev 13: 151-155, 2003.
33. Kaufmann K and Thiel G: Epidermal growth factor and platelet-derived growth factor induce expression of Egr-1, a zinc finger transcription factor, in human malignant glioma cells. J Neurol Sci 189: 83-91, 2001.
34. Reynolds A, Leake D and Boese Q: Rational siRNA design for RNA interference. Nat Biotechnol 22: 326-330, 2004.
35. Baron V, Vo C and Mercola D: A combination study of Egr-1 antisense with chemotherapeutic drugs in human prostate cancer cells. Oncogene 22: 4194-4204, 2003.
36. Baron V, Adamson ED, Calogero A, Ragona G and Mercola D: The transcription factor Egr1 is a direct regulator of multiple tumor suppressors including TGF beta 1, PTEN, p53, and fibronectin. Cancer Gene Ther 13: 115-124, 2006.
37. Virolle T, Adamson ED, Baron V, Birle D, Mercola D, Mustelin T and De Belle I: The Egr-1 transcription factor directly activates PTEN during irradiation-induced signalling. Nat Cell Biol 3: 1124-1128, 2001.
38. De Belle I, Huang RP, Fan Y, Liu C, Mercola D and Adamson ED: p53 and Egr-1 additively suppress transformed growth in HT1080 cells but Egr-1 counteracts p53-dependent apoptosis. Oncogene 18: 3633-3642, 1999.
39. Svaren J, Ehrig T, Abdulkadir SA, Ehrengruber MU, Watson MA and Milbrandt J: EGR1 target genes in prostate carcinoma cells identified by microarray analysis. J Biol Chem 275: 38524-38531, 2000.
40. Liu C, Yao J, Mercola D and Adamson E: The transcription factor EGR-1 directly transactivates the fibronectin gene and enhances attachment of human glioblastoma cell line U251. J Biol Chem 275: 20315-20323, 2000.
41. Zhao-Ling Q, Ping Z, Ming-Mei C and Zhong-Tian Q: siRNAs targeting terminal sequences of the SARS-associated coronavirus membrane gene inhibit M protein expression through degradation of M mRNA. J Virol Methods 145: 146-154, 2007.
42. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE and Mello CC: Potent and specific genetic interference by double-stranded RNA in C. elegans. Nature 391: 806-811, 1998.
43. Plasterk RH: RNA silencing: the genome's immune system. Science 296: 1263-1265, 2002.
44. Tijsterman M and Plasterk RH: Dicers at RISC; the mechanism of RNAi. Cell 117: 1-3, 2004.